The Safety of Embryonic Stem Cell Therapy Relies on Teratoma Removal
Open accessAbstract
Heterotopic transplantation of pluripotent stem cells (PSCs) produces growths known as teratomas (Greek word for monstrous), which consist of a heterogeneous amalgamation of fetal-like tissues. Engraftment of even a few undifferentiated cells is potentially sufficient for teratoma formation. Such an event would have far reaching consequences for the future of this field. Current differentiation protocols produce cultures with unknown degrees of purity and are therefore potentially hazardous. We provide here a succinct overview of current methods and outline challenges for the removal of residual teratoma-initiating cells. Retrospective and prospective approaches for teratoma depletion have been the subject of significant investigation. Retrospective removal includes standard
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pluripotent stem cells can be differentiated into cell types unable to form teratomas by selecting against residual pluripotent cell markers after differentiation.
“This can be achieved after cell differentiation by selecting against residual pluripotent cell markers77.”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587 · see citing works
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512 · see citing works
Tang, C. Z., Lee, A. S., Volkmer, J.-P., Sahoo, D., Nag, D., Mosley, A. R., Inlay, M. A., Ardehali, R., Chavez, S. L., Pera, R. A. R., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1947 · Cited by 376 · see citing works
Self-citationCOMBINED MANAGEMENT OF MALIGNANT TERATOMA OF THE TESTIS
Peckham, M., Barrett, A., McElwain, T. J., et al. (1979) · The Lancet · doi:10.1016/s0140-6736(79)90288-5 · Cited by 249 · see citing works
Bieberich, E., Silva, J., Wang, G., Krishnamurthy, K., & Condie, B. G. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200405144 · Cited by 170 · see citing works
Wang, Y. C., Nakagawa, M., Garitaonandia, I., Slavin, I., Altun, G., Lacharite, R. M., Nazor, K. L., Tran, H. T. T., Lynch, C. L., Leonardo, T. R., et al. (2011) · Cell Research · doi:10.1038/cr.2011.148 · Cited by 93 · see citing works
Schriebl, K., Satianegara, G., Hwang, A., et al. (2011) · Tissue Engineering Part A · doi:10.1089/ten.tea.2011.0311 · Cited by 70 · see citing works
Naujok, O., Kaldrack, J., Taivankhuu, T., Jörns, A., & Lenzen, S. (2010) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9148-z · Cited by 35 · see citing works
Flagged first, then by citations
Research works printed but not linked: 8
- [1]Peckham MJ McElwain TJ Barrett A Lancet 1979 2 267 270 88606
- [2]Di Stasi A Tey SK Dotti G N Engl J Med 2011 365 1673 1683 22047558 PMC3236370
- [3]Naujok O Kaldrack J Taivankhuu T Stem Cell Rev 2010 6 450 461 20411442
- [4]Schriebl K Satianegara G Hwang A Tissue Eng Part A 2012 0 1 11 22092252
- [5]Bieberich E Silva J Wang G J Cell Biol 2004 167 723 734 15545317 PMC2172580
- [6]Hacein-Bey-Abina S Von Kalle C Schmidt M Science 2003 302 415 419 14564000
- [7]Tang C Lee AS Volkmer JP Nat Biotechnol 2011 29 829 834 21841799 PMC3537836
- [8]Wang YC Nakagawa M Garitaonandia I Cell Res 2011 21 1551 1563 21894191 PMC3364725
Cited by
Sorted by citations
Ioannidis, J. P. A., Kim, B. Y. S., & Trounson, A. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0314-y · Cited by 175 · see citing works
- Authors
- Tang, C., Weissman, I. L., & Drukker, M.
- Affiliations
- Stanford University (US)
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2012-01-28
- Volume
- 3
- Issue
- 1
- Pages
- 7-8
- ISSN
- 1949-2553 (ISSN-L)
- PMC
- PMC3292887
- OpenAlex
- W2126766304
- Cited by
- 12
- References
- 8
- Citations by year
- 2024: 1 · 2023: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 3 · 2013: 2
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Oncotarget (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Site cant be reached (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
- Keywords
- teratoma, embryonic stem cells, pluripotent stem cells, heterotopic transplantation, stem cell therapy safety, teratoma formation
- MeSH terms
- Animals, Graft vs Host Disease, Humans, Teratoma, Gene Expression Regulation, Neoplastic, Cell Death, Stem Cell Transplantation, Genes, Transgenic, Suicide, Embryonic Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
